Patent details

LUC00246 Product Name: bimekizumab

  • Data
  • Documents

Basic Information

Publication number:
LUC00246
Type:
SPC
SPC Type:
Medical
Basic Patent Number:
EP127004331
Legal Status:
Inactive
Application number:
LUC00246
First applicant's nationality:
Procedural language:
French

Marketing Authorization

Marketing Authorization Number:
EU/1/21/1575
Marketing Authorization Type:
Marketing Authorization Date:
23/08/2021
Marketing Authorization Status:
Accepted
Marketing Authorization Country:
Luxembourg (LU)

Dates

Filing date:
22/12/2021
First Marketing Authorization date:
23/08/2021
Grant date:
03/02/2025
Activation date:
Publication date:
24/12/2021
Lapsed date:
Expiration date:
Renunciation date:
Revocation date:
Annulment date:
Basic SPC Expiration:
23/08/2036
SPC Extension Expiration:
23/08/2036
Rejection date:
Withdrawal date:

Owner

From:
22/12/2021
 
 

Name:
UCB BIOPHARMA SRL
Address:
Allée de la Recherche 60, 1070, Brussels, Belgium (BE)

Agent

Name:
ARONOVA S.A.
From:
22/12/2021
Address:
PO Box 327, L-4004, ESCH-SUR-ALZETTE, Luxembourg (LU)
To:

Publication

Bulletin

1

Bulletin Heading:
SPC1
Bulletin edition number:
2022/01
Publication date:
03/01/2022
Description:
Section C : Published requests for Supplementary Protection Certificates – I1 publication

2

Bulletin Heading:
SPC2
Bulletin edition number:
2025/04
Publication date:
04/03/2025
Description:
Section D : Granted supplementary protection certificates – I2 publication

Annual Fees

Annual Fee Due Date:
02/02/2032
Annual Fee Number:
21
Annual Fee Amount:
410 Euro
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer: